Journey Medical vs Verrica Pharmaceuticals
DERM and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DERM and VRCA compare
Journey Medical is the larger company, worth 2.0 times as much as Verrica Pharmaceuticals ($122M against $61.2M).
Journey Medical grew revenue faster over the last twelve months (17.0% versus −25.7% for Verrica Pharmaceuticals).
Journey Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −189% at Verrica Pharmaceuticals.
Journey Medical scores higher on the StockData Score (7 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DERM | VRCA |
|---|---|---|
| Size and price | ||
| Market cap | $122M | $61.2M |
| Share price | $4.33 | $3.56 |
| Change, 1 year | −52.3% | −6.8% |
| Change, 5 years | −50.7% | −96.9% |
| Beta (5Y) | 0.68 | 1.08 |
| Employees | 58 | 76 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 2 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× (better) | 2.7× |
| P/B | 3.8× | – |
| Fair value | $5.70 | – |
| Margin of safety | 24.1% | – |
| Growth | ||
| Revenue growth (TTM) | 17.0% (better) | −25.7% |
| Revenue growth, 5Y average | 6.8% | – |
| Profitability | ||
| Gross margin | 65.9% | – |
| Operating margin | −2.9% (better) | −184% |
| Net margin | −7.3% (better) | −189% |
| Return on equity | −17.6% | – |
| Return on invested capital | −5.2% | – |
| Financial health | ||
| Debt / equity | 0.79 | – |
| Interest coverage | −0.6× (better) | −21.9× |
| Current ratio | 1.48 | 1.66 (better) |
| Altman Z-score | 0.55 (better) | −14.33 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.8% | 27.1% |
| Held by insiders | 15.3% | – |
| Insider net buying, 12 months | – | $211K |
| Short interest, % of float | 12.9% | – |
Go deeper
- DERM stock overview
- DERM income statement
- DERM valuation and score
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.